Problem
A pharma business selling contrast media to hospitals on a commodity footing — bought largely on price, margins compressing, volumes unpredictable, with nothing binding hospitals beyond the current order.
Action
Shifted from selling product to placing a financed injector installed base, tied to premium supply agreements with minimum annual volume commitments. Added SKU-level price corridors and country discount governance.
Result
Six points of EBIT margin expansion over three years with double-digit annual revenue growth — launched in one market, proved out, then scaled to a second, converting a commodity line into a durable installed-base annuity.